Condition: Venous Thromboembolism · Sponsor: University Hospital, Brest
Venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) is a frequent disease and the third most common cause of cardiovascular death in the world after myocardial infarction and stroke. Anticoagulant therapy drastically reduces the risk of early VTE recurrence and death, but it exposes patients to a substantial risk of bleeding. Hence, determining the optimal duration of anticoagulant treatment for VTE is a major public health issue. When major transient risk factors for VTE are identified (major surgery, immobilization...), patients generally do not need to extend anticoagulation beyond 3 months, whereas for VTE diagnosed in the context of cancer, therapeutic anticoagulation is required for as long as the cancer is considered "active". However, in more than 50% of cases, venous thromboembolic disease occurs spontaneously, i.e. without any significant clinically detectable circumstance (known as unprovoked venous thromboembolic disease). In such patients, the risk of recurrence is high (35% recurrence rate at 5 years, with a 10% risk of death per recurrence). Scientific societies therefore recommend continuing anticoagulant treatment "indefinitely" (i.e. without programming a stop date or long-term treatment). However, this practice exposes these patients to an ongoing, non-negligible increase in the risk of bleeding, which could ultimately exceed the risk of recurrence of venous thrombo-embolic disease. Optimizing anticoagulant thera…
This description comes directly from the study's public registry record.
Francis COUTURAUD, Prof. · +33298347348 · francis.couturaud@chu-brest.fr
Hélène FORTIN-PRUNIER · +33221744115 · helene.fortin-prunier@chu-brest.fr
Always discuss trial participation with your own doctor first.
| CHU Brest | Brest, France, France | Recruiting |
| CHU d'Amiens - Picardie | Amiens, France | Not Yet Recruiting |
| CHU d'Angers | Angers, France | Not Yet Recruiting |
| Hôpital National d'Instruction des Armées Percy | Clamart, France | Not Yet Recruiting |
| CHU de Clermont Ferrand | Clermont-Ferrand, France | Not Yet Recruiting |
| APHP-Colombes | Colombes, France | Not Yet Recruiting |
| CHU de Dijon - Hôpital François Mitterand | Dijon, France | Not Yet Recruiting |
| CH Le Mans | Le Mans, France | Not Yet Recruiting |
| HCL - Hôpital Edouard Herriot | Lyon, France | Not Yet Recruiting |
| APHM - Hôpital la Timone | Marseille, France | Not Yet Recruiting |
| CHU de Montpellier | Montpellier, France | Not Yet Recruiting |
| CHU de Nancy | Nancy, France | Not Yet Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06731244